Ontada dispensing data now includes Florida Cancer Specialists & Research Institute data
Get a clearer view of oral oncology performance after the prescription
Medically integrated dispensing (MID) data is a critical tool for commercial teams. It provides real-time insights into patient access, adherence and treatment patterns, which are essential for optimizing patient outcomes and commercial strategies.
We have expanded our MID footprint by integrating in-office dispensing data from Florida Cancer Specialists & Research Institute (FCS).
Evaluate oral oncology performance with fewer assumptions
Beginning April 1, Ontada will offer in-office oncology dispensing data from FCS, one of the nation’s largest community oncology practices.
Combined with dispensing data from The US Oncology Network, which treats nearly 1 in 4 cancer patients nationwide, this expansion delivers one of the most comprehensive views of oncology dispensing available in one place.
See how oncology care really works in the community
Earlier signal detection
Track adoption and persistence based on observed dispensing activity rather than lagging proxies
Stronger confidence in trend
Reduce the risk of overinterpreting small or skewed samples with a larger and more representative community oncology footprint
More practical performance benchmarks
Evaluate brand and network performance with observed fill rate ranges from the largest community oncology network
Continuity inside Ontada
Perform consistent analyses over time with FCS data integrated directly into Ontada’s dispensing solution
Why Florida Cancer Specialists & Research Institute matters
Florida is one of the most important oncology markets in the U.S. FCS brings deep community reach, high oncology volume and longitudinal dispensing visibility that materially strengthens commercial decision-making.
Know where dispensing data is available so you can align field and marketing efforts to reality
Frequently asked questions
How does this complement claims data?
Claims data remains valuable for understanding utilization and access over time. Dispensing data adds therapy activity from in‑office dispensing, providing earlier visibility into whether therapies are started and continued. Together, these views support a more complete and timely understanding of performance.
How do commercial oncology teams typically use this data?
Teams use dispensing data to assess adoption and persistence earlier, contextualize performance trends and compare results across a broader community oncology footprint. It is commonly used to support launch planning, ongoing performance monitoring and strategy refinement for oral oncology therapies.
Does data include other locations outside of Florida?
Yes, our data provides dispensing visibility across community oncology nationally. FCS represents a critical oncology market, and its addition significantly expands scale and volume, strengthening the representativeness and reliability of dispensing insights used for national analysis.
Is Florida Cancer Specialists & Research Institute data available on its own?
No. FCS data is available only through Ontada. This ensures continuity, governance and integrated analysis within a single, consistent framework.
When will this be available?
Dispensing data including FCS data will be available beginning April 1, 2026
Will this change how we work with Ontada today?
No. Your engagement model remains the same. What changes is the depth, coverage and confidence of the dispensing insights available to support your decisions.